Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial - Summary - MDSpire

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial

  • By

  • Chloe Stanley

  • Ritwika Mallik

  • Nausheen Hamid

  • Friedrich C. Jassil

  • Victoria Reuven

  • Tapiwa Ruwona

  • Samuel J. Dicken

  • Sulmaaz Qamar

  • Benjamin Norton

  • Helen Kingett

  • Andrea Pucci

  • Cormac Magee

  • David Boniface

  • Rachel L. Batterham

  • Kalpana Devalia

  • Jessica Mok

  • Mohamed Elkalaawy

  • John Loy

  • Andrew Jenkinson

  • Haris Markakis

  • Marco Adamo

  • Alanna Brown

  • Janine Makaronidis

  • May 22, 2026

  • 0 min

Share

Objective:

To assess the efficacy of once-weekly semaglutide 2.4 mg in patients with suboptimal weight loss after metabolic and bariatric surgery (MBS).

Key Findings:
  • Add completion rate percentage for clarity.
Interpretation:

Remove unsupported conclusions.

Limitations:
  • The trial is ongoing, and results are not yet available.
  • Limited sample size may affect the generalizability of findings.
Conclusion:

Revise to summarize specific insights expected from the trial.

Original Source(s)

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial

  • by Chloe Stanley, Ritwika Mallik, Nausheen Hamid, Friedrich C. Jassil, Victoria Reuven, Tapiwa Ruwona, Samuel J. Dicken, Sulmaaz Qamar, Benjamin Norton, Helen Kingett, Andrea Pucci, Cormac Magee, David Boniface, Rachel L. Batterham, Kalpana Devalia, Jessica Mok, Mohamed Elkalaawy, John Loy, Andrew Jenkinson, Haris Markakis, Marco Adamo, Alanna Brown, Janine Makaronidis

  • May 22, 2026

Related Content

The RASA2/RASA3 ortholog RasGAP1 modulates obesity-linked phenotypes and is associated with leptin-analog signaling in Drosophila

Global Trends and Research Topics in Gastric Bypass Clinical Trials: A Bibliometric Analysis and Latent Dirichlet Allocation (LDA) Study

Can Uric Acid Distinguish Lipedema From Overweight?

Metabolomics analysis identified higher uric acid levels in patients with lipedema and lymphedema, although associations weakened following adjustment for renal insufficiency.